Upadacitinib

Abstract

Upadacitinib is a small molecule compound that is highly selective for JAK1 and is approved in Japan for the treatment of rheumatoid arthritis, spondyloarthritides, inflammatory bowel diseases, and atopic dermatitis. Since the daily dosage ranges from 7.5mg to 45mg depending on the disease and patient’s condition, it is expected to be of great help in understanding the relationship between efficacy/safety and dosage. Although the drug has shown efficacy in patients refractory to multidrug therapy, as with other JAK inhibitors, herpes zoster and other infectious diseases should be kept in mind. However, there is no evidence to date to suggest that upadacitinib increases the risk of cardiovascular events or malignancy.